ESLA

Estrella Immunopharma, Inc.

1.04 USD
-0.38 (-26.76%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Estrella Immunopharma, Inc. stock is up 9.47% since 30 days ago. The next earnings date is Aug 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 July’s closed higher than June.

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.